Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma

Ashkan Lashkari, Warren A. Chow, Frances Valdes, Lucille Leong, Vu Phan, Przemyslaw Twardowski, Neena Kapoor, Arturo Molina, Zaid Al-Kadhimi, Paul Frankel, George Somlo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options. The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients. Patients and Methods: Thirteen patients were enrolled onto this study. The first cycle of HDCT consisted of doxorubicin (150 mg/m 2) and ifosfamide (14 g/m2) mixed with mesna (14 g/m 2), while the second cycle consisted of melphalan (150 mg/m 2) and cisplatin (200 mg/m2). Results: Eleven out of 13 patients were able to complete both cycles of HDCT. No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. The 5-year progression-free survival (PFS) and overall survival (OS) for all patients was 23% (confidence interval, CI: 0-46%) and 31% (CI: 14-70%), respectively. Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT. Conclusion: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.

Original languageEnglish
Pages (from-to)3281-3288
Number of pages8
JournalAnticancer Research
Volume29
Issue number8
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Autologous Transplantation
Sarcoma
Drug Therapy
Stem Cell Transplantation
Ewing's Sarcoma
Disease-Free Survival
Mesna
Safety
Ifosfamide
Melphalan
Survival
Feasibility Studies
Doxorubicin
Cisplatin
Confidence Intervals
Mortality
Therapeutics

Keywords

  • Autologous transplantation
  • Ewing's sarcoma
  • High-dose chemotherapy
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lashkari, A., Chow, W. A., Valdes, F., Leong, L., Phan, V., Twardowski, P., ... Somlo, G. (2009). Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Research, 29(8), 3281-3288.

Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. / Lashkari, Ashkan; Chow, Warren A.; Valdes, Frances; Leong, Lucille; Phan, Vu; Twardowski, Przemyslaw; Kapoor, Neena; Molina, Arturo; Al-Kadhimi, Zaid; Frankel, Paul; Somlo, George.

In: Anticancer Research, Vol. 29, No. 8, 01.08.2009, p. 3281-3288.

Research output: Contribution to journalArticle

Lashkari, A, Chow, WA, Valdes, F, Leong, L, Phan, V, Twardowski, P, Kapoor, N, Molina, A, Al-Kadhimi, Z, Frankel, P & Somlo, G 2009, 'Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma', Anticancer Research, vol. 29, no. 8, pp. 3281-3288.
Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Research. 2009 Aug 1;29(8):3281-3288.
Lashkari, Ashkan ; Chow, Warren A. ; Valdes, Frances ; Leong, Lucille ; Phan, Vu ; Twardowski, Przemyslaw ; Kapoor, Neena ; Molina, Arturo ; Al-Kadhimi, Zaid ; Frankel, Paul ; Somlo, George. / Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. In: Anticancer Research. 2009 ; Vol. 29, No. 8. pp. 3281-3288.
@article{4bb488e4b8ac40a48e06ac7043a0d808,
title = "Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma",
abstract = "Background: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options. The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients. Patients and Methods: Thirteen patients were enrolled onto this study. The first cycle of HDCT consisted of doxorubicin (150 mg/m 2) and ifosfamide (14 g/m2) mixed with mesna (14 g/m 2), while the second cycle consisted of melphalan (150 mg/m 2) and cisplatin (200 mg/m2). Results: Eleven out of 13 patients were able to complete both cycles of HDCT. No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. The 5-year progression-free survival (PFS) and overall survival (OS) for all patients was 23{\%} (confidence interval, CI: 0-46{\%}) and 31{\%} (CI: 14-70{\%}), respectively. Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT. Conclusion: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.",
keywords = "Autologous transplantation, Ewing's sarcoma, High-dose chemotherapy, Rhabdomyosarcoma",
author = "Ashkan Lashkari and Chow, {Warren A.} and Frances Valdes and Lucille Leong and Vu Phan and Przemyslaw Twardowski and Neena Kapoor and Arturo Molina and Zaid Al-Kadhimi and Paul Frankel and George Somlo",
year = "2009",
month = "8",
day = "1",
language = "English",
volume = "29",
pages = "3281--3288",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma

AU - Lashkari, Ashkan

AU - Chow, Warren A.

AU - Valdes, Frances

AU - Leong, Lucille

AU - Phan, Vu

AU - Twardowski, Przemyslaw

AU - Kapoor, Neena

AU - Molina, Arturo

AU - Al-Kadhimi, Zaid

AU - Frankel, Paul

AU - Somlo, George

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options. The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients. Patients and Methods: Thirteen patients were enrolled onto this study. The first cycle of HDCT consisted of doxorubicin (150 mg/m 2) and ifosfamide (14 g/m2) mixed with mesna (14 g/m 2), while the second cycle consisted of melphalan (150 mg/m 2) and cisplatin (200 mg/m2). Results: Eleven out of 13 patients were able to complete both cycles of HDCT. No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. The 5-year progression-free survival (PFS) and overall survival (OS) for all patients was 23% (confidence interval, CI: 0-46%) and 31% (CI: 14-70%), respectively. Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT. Conclusion: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.

AB - Background: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options. The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients. Patients and Methods: Thirteen patients were enrolled onto this study. The first cycle of HDCT consisted of doxorubicin (150 mg/m 2) and ifosfamide (14 g/m2) mixed with mesna (14 g/m 2), while the second cycle consisted of melphalan (150 mg/m 2) and cisplatin (200 mg/m2). Results: Eleven out of 13 patients were able to complete both cycles of HDCT. No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. The 5-year progression-free survival (PFS) and overall survival (OS) for all patients was 23% (confidence interval, CI: 0-46%) and 31% (CI: 14-70%), respectively. Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT. Conclusion: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.

KW - Autologous transplantation

KW - Ewing's sarcoma

KW - High-dose chemotherapy

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=68549104150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549104150&partnerID=8YFLogxK

M3 - Article

C2 - 19661346

AN - SCOPUS:68549104150

VL - 29

SP - 3281

EP - 3288

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -